The Longevity Show with Dr. Hillary Lin

Hillary Lin, MD
  • 5.0 (6)
  • Health & Fitness
  • Updated Daily

Longevity is about choice. Stanford-trained, board-certified internist Hillary Lin explores the medicine, science and technologies expanding what we can do with our lives. Through conversations with clinicians, researchers and builders, and her own experience in practice, she explains promising tools, real tradeoffs and the decisions behind better health. Hillary is co-founder and CEO of CareCore and writes The Longevity Letter. More years. More choices. Explore the show and free resources at hillarylinmd.com/podcast. Educational content, not personal medical advice.

  1. Sep 22

    Peptides: What I’m Not Seeing in My Patients | Dr. Mayoni

    I’ve heard plenty of big promises about peptides. What I’m seeing in practice is a lot less dramatic, with an important exception: GLP-1s. In this conversation with Dr. Mayoni Gooneratne, we talk about what the evidence can tell us, why the source of an injectable matters, and how GLP-1s fit into conversations about women’s health, nutrition and muscle. We also get into the difference between off-label prescribing, compounded medicines and products sold for research use, and why a promising idea is only one part of the decision. Original conversation hosted by Dr. Mayoni Gooneratne and shared with permission. Learn more about Dr. Mayoni: https://drmhumanhealth.co.uk/dr-mayoni Chapters 00:00 Peptides Beyond GLP-1s 00:25 Off-Label Prescribing & FDA Approval 01:37 Compounding Pharmacies vs. "Research Use" Labs 04:36 Sourcing Safety & Why Batch Testing Matters 06:38 What Can Go Wrong? (ICU Case) 07:34 Beyond Compounds: Lifestyle Medicine First 09:02 Women’s Health, Perimenopause & GLP-1s 11:05 Sustainable Weight Loss & Muscle Preservation 13:48 Final Advice: Beating the Peptide FOMO References: FDA: off-label use — https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/understanding-unapproved-use-approved-drugs-label FDA: compounding — https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers FDA: BPC-157 briefing — https://www.fda.gov/media/193343/download This conversation is for education, not personal treatment advice. Discuss medication changes with your clinician.

  2. Sep 17

    Your Inflammation Test Is High. Are You Actually Inflamed?

    Your inflammation test is high. Before you try to lower the number, find out what it actually measured. I explain why ESR, CRP, hsCRP and ferritin can tell different stories, what newer tests such as GlycA can add, and why a treatment that lowers a marker still has to prove that people do better. We’ll look at a frightening CRP result that settled on repeat testing, a ferritin result that prompted a closer look, and the heart-disease trials that separate a better lab number from a better outcome. Read the full guide: https://hillarylinmd.com/guides/inflammation-markers-crp-esr-ferritin Clinical examples combine and change details to protect privacy. This is education, not personal medical advice. Interpret your results with your symptoms, history, other tests and clinician. Chapters: 00:00 What a High Inflammation Result Means 00:24 ESR: What the Falling Blood Cells Tell Us 04:41 CRP: Why a High Result Can Disappear 08:42 hsCRP and Cardiovascular Risk 09:23 Ferritin: Iron Stores and Misleading Results 14:02 What hsCRP Predicted, and What JUPITER Tested 18:30 GlycA, Glycan Age and the Limits of Newer Tests 23:03 Do Lower Markers Mean Better Health?

  3. Sep 10

    Fake AI Doctors Are Here. Real Doctors Need to Show Up.

    Patients already get health advice from their feeds. What happens when the “doctor” on screen isn't a person? In this Ultralight conversation, Sunita Mohanty and I talk about why real clinicians need a public voice, and how to start when posting feels unnatural and clinic already takes everything you've got. We cover the three layers of a physician's online presence, choosing a platform that fits how you think, using AI for research without handing over your judgment, and why you should make your first videos before paying an agency to make them for you. The point is to build trust with people you can help. Start with why you're posting, learn what works, and keep an audience you can reach beyond an algorithm. Read the companion playbook: https://hillarylinmd.com/guides/social-media-for-physicians For clinicians and health builders, join The CareCore Stack: https://stack.carecore.io/subscribe Chapters 00:00 Fake Doctors And Trust Online 03:49 Why Doctors Hesitate To Post 05:11 The Three Layers Of Clinician Content 08:39 Find Your Why And Choose A Platform 13:28 Why Healthcare Needs More Than Viral Content 15:49 Clinicians As Educators And Storytellers 17:30 Getting Started With AI Research And Stories 24:04 Develop Your Taste Before Hiring An Agency 26:32 Build An Audience Beyond Social Platforms Featuring Hillary Lin, MD, in conversation with Sunita Mohanty of Ultralight.

  4. Aug 14

    My LDL Was 192. Then I Found the First PCSK9 Pill.

    My LDL was 192 even though I felt healthy. That result sent me into the story of PCSK9—a protein discovered outside cholesterol research that became the target of injections, RNA silencing, the first oral PCSK9 inhibitor, and now one-time gene-editing experiments. This episode follows the human genetics, LDL-receptor biology, and three engineering problems behind Lipfendra/enlicitide. The pill has proven potent LDL and ApoB lowering; its dedicated cardiovascular-outcomes trial is still ongoing. 𝘋𝘐𝘚𝘊𝘓𝘈𝘐𝘔𝘌𝘙: 𝘛𝘩𝘪𝘴 𝘷𝘪𝘥𝘦𝘰 𝘪𝘴 𝘧𝘰𝘳 𝘦𝘥𝘶𝘤𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘢𝘯𝘥 𝘪𝘯𝘧𝘰𝘳𝘮𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘱𝘶𝘳𝘱𝘰𝘴𝘦𝘴 𝘰𝘯𝘭𝘺 𝘢𝘯𝘥 𝘥𝘰𝘦𝘴 𝘯𝘰𝘵 𝘤𝘰𝘯𝘴𝘵𝘪𝘵𝘶𝘵𝘦 𝘮𝘦𝘥𝘪𝘤𝘢𝘭 𝘢𝘥𝘷𝘪𝘤𝘦. 𝘈𝘭𝘸𝘢𝘺𝘴 𝘤𝘰𝘯𝘴𝘶𝘭𝘵 𝘸𝘪𝘵𝘩 𝘺𝘰𝘶𝘳 𝘩𝘦𝘢𝘭𝘵𝘩𝘤𝘢𝘳𝘦 𝘱𝘳𝘰𝘧𝘦𝘴𝘴𝘪𝘰𝘯𝘢𝘭 𝘳𝘦𝘨𝘢𝘳𝘥𝘪𝘯𝘨 𝘱𝘦𝘳𝘴𝘰𝘯𝘢𝘭 𝘮𝘦𝘥𝘪𝘤𝘢𝘭 𝘤𝘰𝘯𝘥𝘪𝘵𝘪𝘰𝘯𝘴, 𝘥𝘪𝘢𝘨𝘯𝘰𝘴𝘪𝘴, 𝘰𝘳 𝘵𝘳𝘦𝘢𝘵𝘮𝘦𝘯𝘵 𝘱𝘭𝘢𝘯𝘴. Chapters: 00:00 The Inherited Risk: My LDL Was 192 and the First Oral PCSK9 Is Here 02:36 Nature’s Human Experiment: The Dallas Heart Study & The 88% Risk Drop 05:40 The Zero-PCSK9 Human: What Living with an LDL of 14 Proves 07:10 The Disposal Tag: How PCSK9 Destroys Your Artery Clearance 08:42 The Evolution of PCSK9 Inhibitors: From Antibodies to RNA 12:02 Evolution in a Test Tube: Engineering the First Oral PCSK9 Pill 16:04 The Practical Inversion: Why a Daily Pill Can Be Harder Than an Injection 18:04 One Injection for Life: The Promise and Risk of Permanent Gene Editing 21:12 What This Means for You: Managing Family History, Risk, and Daily Reality

  5. Aug 4

    What Human Longevity Found After Screening 10,000 “Healthy” People

    A corrected version of this episode is here: https://youtu.be/SG1aq_6vkFI What happens when you run deep, whole-body imaging and genetic sequencing on 10,000 people who feel completely healthy? Dr. Wei-Wu He, Chairman and CEO of Human Longevity, Inc. (HLI), joins Dr. Hillary Lin to break down the realities of precision medicine and the hidden risks lurking in asymptomatic patients. They discuss why standard population medicine might miss your individual risk, how polygenic risk scores are changing cardiovascular prevention, and his vision for democratizing these life-saving screenings for everyone. About the Guest:  Dr. Wei-Wu He is the Chairman and CEO of Human Longevity, Inc. (HLI), bringing over 40 years of experience in molecular biology and biotechnology to the forefront of proactive healthcare. A seasoned biotech entrepreneur and investor, his career has been dedicated to advancing genomics and precision medicine. Under his leadership, HLI is combining whole-genome sequencing, advanced imaging, and artificial intelligence to democratize data-driven, preventative medicine and extend the human healthspan. Disclaimer: The patient outcomes and case studies discussed in this episode are company-reported observational findings by Human Longevity, Inc., not independently verified clinical trials. Screening data should always be interpreted by a qualified clinician. A test earns its place when it changes a medical decision and includes a responsible follow-up plan. Chapters: 00:00 What Happens When Healthy People Get Screened? 00:21 The Silent Risks: Aneurysms, Tumors, and Arterial Plaque 03:04 The Compound Effect of "Rare" Diseases 05:09 Lifespan Heritability: Is 50% of Your Life Predetermined? 05:48 Monogenic vs. Polygenic Risk Scores (PRS) 06:49 Predicting Heart Attack Risk 12 Years in Advance 10:52 Family History vs. Your Actual Genome 12:46 Inside HLI: The CEO's Vision for Data Collection 14:13 Case Study: Stool-DNA, Colonoscopy, and Appendiceal Cancer 17:04 Population Medicine vs. Individual Risk Dr. Lin's Longevity Tips & Newsletter: hillarylinmd.com/go/ytLinkedIn: linkedin.com/in/hillarylinmdAbout Dr. Hillary Lin: hillarylinmd.comExplore CareCore: carecore.ioHuman Longevity, Inc (HLI): https://www.humanlongevity.com/

  6. Jul 20

    The Fitness Decline You Won’t See Coming (Even With “Good” Labs)

    Your annual blood work looks perfect—but what happens when you hit a physical stressor, catch a virus, or simply start aging? Most standard labs are designed to detect disease, but they completely miss your physiologic reserve. In this episode, Dr. Hillary Lin sits down with Brooks Leitner to discuss why VO₂ max should be treated as a clinical vital sign. Using VO Health’s early-stage blood-based proteomics as a fascinating case study, we dive into how the body actually delivers oxygen under stress, why wearable estimates aren't the whole truth, and how you can actually build a "bad-day buffer" for your long-term health. 🔍 What We’ll Cover The "Normal Labs" Trap: Why perfect blood work can hide dangerously low physical reserve.Your "Bad-Day Buffer": How to build resilience for unexpected physical stress like illness or surgery.The Missing Vital Sign: Why fitness should be checked right alongside your blood pressure.Oxygen Under Stress: What VO₂ max actually measures across your entire cellular engine.The Mortality Signal: The data linking higher fitness to a longer life, and what the studies really mean.VO₂ Max Blind Spots: Why cardio alone isn't enough to build true physical resilience.Data vs. Reality: Why mismatches between your smartwatch and your actual performance are valuable signals.Where to Start: A practical, zero-equipment method to start building your reserve today. Chapters 00:00 Why Normal Labs Miss The Mark 00:47 What Routine Blood Work Gets Wrong About Health 02:03 Defining True Resilience And Hormesis 04:34 The Shocking Decline In Population Fitness 06:32 Cardiorespiratory Fitness: The Missing Vital Sign 10:29 The Oxygen Cascade: How VO2 Max Actually Works 12:55 The Surprising Data Linking VO2 Max To Mortality 15:50 Improving VO2 Max: Is It Possible? 17:55 Weight Loss, Muscle Mass, And Gaming Your VO2 Max 23:54 Heart Rate Training Zones And The Problem With METs 29:21 Why Endurance Training Won't Maximize Your VO2 Max 32:00 What VO2 Max Completely Misses (Strength And Grip) 35:20 Sauna, Altitude, And Drugs For VO2 Max 42:08 Proteomics: Estimating Your VO2 Max From A Blood Test 49:00 Wearables and Their Accuracy in Measuring Fitness 51:53 The Ultimate Zero-Equipment Hack To Build VO2 Max Get Dr. Hillary Lin’s free longevity tips and newsletter: https://hillarylinmd.com/go/yt Learn more about the podcast: https://hillarylinmd.com/podcast LinkedIn: https://www.linkedin.com/in/hillarylinmd/ Learn more about Dr. Hillary Lin: https://www.hillarylinmd.com/ Explore CareCore: https://carecore.io VO Health: https://vohealth.co/

  7. Jul 13

    High ApoB, CAC Zero: What Your Heart Tests Are Really Saying

    High ApoB but clean metabolic labs. CAC zero but inherited Lp(a). A normal stress test but plaque on CCTA. This is where heart-disease prevention gets noisy. In this advanced episode, I walk through how I read conflicting heart-risk signals without letting one lab, scan, or internet camp hijack the whole conversation. The map is simple: particle traffic, the artery wall, blood pressure and metabolic terrain, visible plaque, and the clot we are trying to prevent. We cover ApoB, LDL-C, LDL-P, particle size, Lp(a), APOE4, CAC, CCTA, CIMT, stress testing, inflammation, plaque reversal, statin concerns, supplements, and what actually changes the next decision. Use this as education and a framework for better clinician conversations, not a personal treatment plan. Chapters 00:00 Why Heart Tests Seem To Disagree 01:43 The Map: Particles, Wall, Terrain, Plaque, Event 06:22 Where Plaque Actually Begins 10:07 Why Evolution Left Us Vulnerable 13:22 ApoB, LDL-C, LDL-P, Particle Size, Remnants, Lp(a) 25:54 High ApoB With Clean Metabolic Markers 30:51 Blood Pressure, Inflammation, And “Terrain” 35:37 APOE4, Family History, And Inherited Clues 40:38 CAC, CCTA, CIMT, Stress Tests, And AI Plaque Analysis 48:26 How To Read Conflicting Signals In Real Life 50:26 Plaque Reversal, Stabilization, And What Counts As Proof 54:18 Statins, Side Effects, Red Yeast Rice, And Supplement Claims 01:09:45 The Takeaway: Do Not Let One Marker Become The Whole Story

  8. Jun 10

    Why One Hormone Test Can Miss the Whole Story

    Hormones are not single data points. Cortisol, progesterone, testosterone, and other hormones change across the day, cycle, sleep, stress, training, and context.In this episode, Dr. Hillary Lin talks with Marina Pavlovic Rivas, cofounder and CEO of Eli Health, about why one annual lab snapshot can miss dynamic physiology — and why more data still needs humility.We cover: saliva testing and what it can/can’t showcortisol curves vs cortisol panicprogesterone/testosterone trackingwellness data vs diagnosticswhy validated at-home testing is hardhow AI in healthcare depends on better inputsEducational only, not medical advice.Chapters: 00:00 The Importance of Hormonal Health00:54 The Data Gap in Hormone Health02:43 The Science Behind At-Home Saliva Testing06:17 Understanding Cortisol and Its Impact12:14 Personalizing Cortisol Data vs. Wearable Tracking Limitations15:05 Identifying Overtraining and "Tired but Wired" States18:43 Expanding into Sex Hormones: Progesterone & Testosterone20:40 Tracking Protocols: Finding Trends vs. Creating Noise23:44 The "Anytime, Anywhere" Design Philosophy24:40 Understanding Cortisol and Performance28:31 Factors Influencing Testosterone Levels31:36 Regulatory Boundaries: Wellness vs. Clinical Diagnostics35:18 The Future of Data in Personalized Medicine37:39 The Realities of Deep-Tech Health R&D39:04 Closing Insights for Longevity and Health-Tech FoundersGet Dr. Hillary Lin’s free longevity tips and newsletter: https://www.hillarylinmd.com/subscribe Learn more about Dr. Hillary Lin: https://www.hillarylinmd.com/ Explore CareCore: https://carecore.io

    Why One Hormone Test Can Miss the Whole Story
See All (106)

Ratings & Reviews

5
out of 5
6 Ratings

About

Longevity is about choice. Stanford-trained, board-certified internist Hillary Lin explores the medicine, science and technologies expanding what we can do with our lives. Through conversations with clinicians, researchers and builders, and her own experience in practice, she explains promising tools, real tradeoffs and the decisions behind better health. Hillary is co-founder and CEO of CareCore and writes The Longevity Letter. More years. More choices. Explore the show and free resources at hillarylinmd.com/podcast. Educational content, not personal medical advice.

Information

You Might Also Like